ADCT ADC Therapeutics SA
P/E
--
Forward P/E
--
Price/Sales
2.422
Beta
1.861
Div Yield
--
Market Cap
--
Company Analysis
Latest News
ADC Therapeutics SA Q3 2026 Earnings Preview: What Analysts Expect on November 09, 2026
ADC Therapeutics is expected to report Q3 2026 revenue of $22.52 million and an EPS loss of $0.21, with its current $3.45 share price trading significantly...
ADC Therapeutics preliminary third quarter 2026 revenue rose 31% to $21M alongside robust clinical data
ADC Therapeutics reported preliminary net product revenue for the third quarter 2026 of $21 million, compared to $16 million in the prior year period. The...